Tenet Healthcare heads into its October 27 Q3 earnings report with options traders rotating to a notably more bullish stance — a sharp break from months of defensive positioning.
The clearest signal right now is in options. The put/call ratio has fallen to 0.94, more than two standard deviations below its 20-day average of 1.11 — making this one of the most call-heavy readings of the past year. For context, the PCR spent most of August and September above 1.15, meaning the shift over the past two sessions is abrupt. Investors appear to be reaching for upside exposure heading into the print rather than hedging downside, a marked change in posture.
The lending market tells a story of almost no short-side conviction. Short interest is just 2.1% of the free float — and that figure has fallen 37% over the past month, dropping from roughly 3 million shares in August to under 1.9 million today. Borrow costs have collapsed alongside it, falling nearly 59% on the week to just 0.16%, close to the floor. Availability is extraordinarily loose at 3,880% — meaning the pool of shares available to borrow dwarfs what is actually shorted. There is no squeeze dynamic here, no crowding, and no meaningful short-side overhang to constrain a further rally.
The Street picture is broadly constructive, though BMO Capital's fresh initiation at Market Perform — with a $265 target essentially at the current price of $262 — introduces a note of caution. Bulls at Leerink Partners, UBS, Truist, and Guggenheim carry targets ranging from $283 to $309, all comfortably above spot, and most of those targets were raised sharply after Q2. Wells Fargo lifted its target from $231 to $281 in early August. The consensus rating is technically a hold, reflecting some scepticism about subsidy headwinds — the bear case centres on an anticipated $220 million headwind to the Acute segment if ACA subsidies expire, which could strip coverage from a large portion of the patient mix. The bulls counter with USPI segment momentum, improved payer mix, and margin visibility. On valuation, the P/E has drifted down about 7% over the past month to 12.4x, and EV/EBITDA is a modest 7.6x — not expensive for a healthcare services operator with a 92nd-percentile EPS surprise score.
Insider selling is the one note of friction worth flagging. In the 90 days through September 14, insiders net sold roughly 186,000 shares worth close to $50 million. The CEO sold over $13.7 million of stock on August 25 alone, and the COO added another $6.4 million the same day. None of the disclosed trades were executed under 10b5-1 pre-arranged plans, which makes them discretionary rather than scheduled. Two directors also sold in September at prices around $263-$264 — near where the stock trades today. The volume is notable relative to the float, even if the sell-off has not dented the institutional picture: T. Rowe Price holds over 10.8% and added more than a million shares in the most recent period, and BlackRock crossed 10% with a fresh 13G/A filing in early September.
The earnings history adds colour. The last Q2 print on July 28 sent the stock up nearly 6% the following day and 4% over the week. A prior event in late July — with an overlapping announcement — saw a one-day move of 22% and a five-day gain of 28%. Tenet has a 92nd-percentile EPS surprise score, so the pattern of beats is well established. The Q3 print on October 27 is therefore less about whether the operational story holds and more about whether management guides through the subsidy expiry risk with enough confidence to keep institutional buyers on board.
See the live data behind this article on ORTEX.
Open THC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
